SCHEMBL27157338

SCHEMBL27157338

CC(C)(C)OC(=O)N1CCCC(C(=O)NNC(=O)c2ccccc2F)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.50
▸ KAT7 O95251 1/20 0.47
▸ KAT8 Q9H7Z6 1/20 0.47
▸ USP30 Q70CQ3 2/20 0.46
▸ EPHX2 P34913 1/20 0.46
▸ ABL1 P00519 1/20 0.45
▸ RIN1 Q13671 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ GAA P10253 2/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ SCN9A Q15858 1/20 0.43
▸ ACKR3 P25106 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27157329 0.88 KMT2A (0.48) KMT2AKAT7KAT8USP30EPHX2
SCHEMBL27157319 0.86 KMT2A (0.47) KMT2AKAT7KAT8USP30ABL1
SCHEMBL27157330 0.85 KMT2A (0.62) KMT2AUSP30ABL1RIN1MEN1
SCHEMBL1861675 0.85 RAB9A (0.53) KMT2AKAT7KAT8USP30MEN1
SCHEMBL5593571 0.85 RAB9A (0.53) KMT2AKAT7KAT8USP30MEN1
SCHEMBL27157406 0.83 KMT2A (0.46) KMT2AKAT7KAT8USP30ABL1
SCHEMBL30025353 0.83 KMT2A (0.46) KMT2AKAT7KAT8USP30ABL1
SCHEMBL5871130 0.82 KMT2A (0.60) KMT2AUSP30EPHX2ABL1RIN1
SCHEMBL1867619 0.79 GAA (0.49) KMT2AUSP30MEN1ALDH1A1MAPT
SCHEMBL3617205 0.79 GAA (0.49) KMT2AUSP30MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246952-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2024-07-25 — — US disclosed
CN-117751114-A Small molecule modulators of glucocerebrosidase activity and uses thereof 凡况生化公司 2024-03-22 — — CN disclosed
EP-4329880-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-03-06 — — EP disclosed
WO-2022232360-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246952-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 KMT2A 3498/4885KAT7 2395/4885KAT8 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback